An observational study in Cystic Fibrosis (CF), Pregnancy and Infant, Newborn, sponsored by Royal Brompton & Harefield NHS Foundation Trust. Recruiting at 1 site in United Kingdom. Per ClinicalTrials.gov, last updated 2025-10-01.
Sponsored by Royal Brompton & Harefield NHS Foundation Trust · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 16 studies in Cystic Fibrosis by Royal Brompton & Harefield NHS Foundation Trust — 3 open to participants now, 4 under way, none of them phase 3. Cystic Fibrosis · Royal Brompton & Harefield NHS Foundation Trust.
Among the 16 studies in Cystic Fibrosis by Royal Brompton & Harefield NHS Foundation Trust, this one is the only one that started in 2025, is one of 5 observational ones, and was the 14th registered.
1,622 studies on the registry are indexed under Cystic Fibrosis; 201 are open to participants now.
Browse Cystic Fibrosis studies →3 of the 16 studies in Cystic Fibrosis by Royal Brompton & Harefield NHS Foundation Trust are open now, in 1 country. Recruiting first, the newest first:
Royal Brompton & Harefield NHS Foundation Trust · Sites in United Kingdom
Ages 16+
Royal Brompton & Harefield NHS Foundation Trust · Sites in United Kingdom
Ages 16+ · Healthy volunteers
By country, each count listing its studies:
Of the 156 Cystic Fibrosis studies recruiting now, 95 (61%) set no upper age limit and 45 (29%) stop at 75 or younger; 87 take children under 18; 42 take healthy volunteers.
This study: all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
16 studies; the count open now beside each. This study's row is marked.
First in 1999; this study’s year is marked. 1 started in 2025.
This study's planned enrollment of 60 is below the median of 86 across 504 observational studies indexed under Cystic Fibrosis.
Median enrollment 50 across the 11 interventional studies, 70 across the 5 observational. Of the 10 that completed or were terminated, 0 (0%) have results posted.
This tab as a report to print or save as PDF → With an account.
Royal Brompton & Harefield NHS Foundation Trust is the lead sponsor of 141 studies on the registry; 21 are open to participants now.
1 of the studies in Cystic Fibrosis by Royal Brompton & Harefield NHS Foundation Trust that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07879651Royal Brompton & Harefield NHS Foundation TrustSPutum Induction and Nebuliser deviCEs for Patients With CF | 2027-06 |
Add it to your calendar (.ics) → With an account.
Among the 16 studies in Cystic Fibrosis by Royal Brompton & Harefield NHS Foundation Trust, from their registry updates:
This tab as a report to print or save as PDF → With an account.
In this study, investigators aim to study in detail the physical (including nutritional and pulmonary) and mental health of females with cystic fibrosis (CF) planning a pregnancy, during pregnancy, and in the early parenthood period.
Additionally the health of offspring in infancy and early life will be studied to understand if further screening investigations or clinical care models should be part of clinical guidelines
Improvements in treatments for people with CF have meant that more are becoming pregnant. CFTR modulators (CFTRm) are one of these treatments. They work by tackling the underlying cause of CF. These changes have created a need and an opportunity for research into the health and experiences of people with CF and their children in the CFTRm era.
The study is called 'MATRIARCH_CF' and includes 3 related sub-studies:
'Mama' is enrolling participants aged 16 years or older with CF under the care of the Royal Brompton Hospital (RBH) adult CF Unit who are planning a pregnancy or pregnant. The aim is to describe the impact of pregnancy and the first 12-24 months of parenthood in females with CF on their physical and psychological health. Investigations in eight visits include blood tests, lung function, imaging, and interviews.
'Mini' is enrolling biological offspring of people with CF (mothers and fathers) cared for by the RBH Adult CF Service, from birth to age two. The aim is to collect information that will allow for assessment of health outcomes in offspring of parents with CF in the short term. There will be up to four visits over two years with investigations including blood tests, sweat tests, and brain ultrasound.
'Midi' explores the same question as 'Mini' but in the longer term for those aged three-to-six. There will be up to two visits, and they include lung function testing and a lung MRI.
This study is described as 'observational' as investigators will not provide or change any treatment. Participant's health will be monitored with a range of investigations, many of which are optional. Knowledge gained from this study will be used to create guidelines to help families with CF and their medical teams make decisions around pregnancy and their offspring.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
'Mama' sub-study:
'Mini' sub-study:
'Midi' sub-study:
Exclusion Criteria:
'Mama' sub-study:
'Mini' sub-study:
'Midi' sub-study:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Females with Cystic Fibrosis who are pregnant or planning a pregnancy
Children aged 0-24 months with one biological parent who has a diagnosis of cystic fibrosis
Children aged 3-6 years with one biological parent who has a diagnosis of cystic fibrosis
Change in FEV1
Change in FEV1 percent predicted (ppFEV1) from pre-conception/baseline to end of pregnancy, and at 12- and 24-months post-partum.
Time frame: 9 months
Incidence of CF-related pulmonary complications during pregnancy.
Time frame: 9 months
Incidence of premature delivery
Defined as birth \<37 weeks gestation.
Time frame: 3 years
Frequency of liver dysfunction in infants
Defined as ALT/AST/GGT/bilirubin above upper limit of normal using laboratory normal ranges. This is prospectively obtained in the 'Mini' sub-study, and retrospectively reviewed from medical records in the 'Midi' sub-study.
Time frame: 2 years
Incidence of congential abnormalities
Based on medical history and examination
Time frame: 3 years
Frequency of CF diagnoses in infants despite negative newborn screen testing
The number of participants with normal IRT subsequently diagnosed with CF (based on a combination of CF genetic tests, sweat chloride, and faecal elastase where appropriate).
Time frame: 3 years
Frequency of abnormal lung clearance index results in young children
A lung clearance index (LCI) measurement above the normal levels as defined by investigating laboratory values (Midi only)
Time frame: 3 years
Started Jun 2025 (actual). Primary completion is estimated for Apr 2028, 34 months after the start.
Of 228 non-industry observational studies under Cystic Fibrosis, half reached primary completion within 40 months of starting (the median), counting those still running; a quarter within 19 and three quarters within 89. This study's planned 34 months is below that.
Counting every sponsor, half of 243 studies reached it within 41 months; a quarter within 19 and three quarters within 79.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Royal Brompton & Harefield NHS Foundation Trust →